Index
RUT
Market Cap
705.65M
Enterprise Value
1.21B
Income
-131.23M
Sales
161.39M
Book/sh
-0.20
Cash/sh
0.64
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
485
IPO
Oct 27, 2010
P/E
-
Forward P/E
-
PEG
-
P/S
4.37
P/B
-
P/C
3.54
P/FCF
-
EV/EBITDA
-
EV/Sales
7.51
Quick Ratio
3.72
Current Ratio
4.62
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.43
EPS next Y
-0.45
EPS next Q
-0.13
EPS this Y
74.96%
EPS next Y
1.72%
EPS next 5Y
41.86%
EPS past 3/5Y
-9.18% -
Sales past 3/5Y
7.64% 15.19%
EPS Y/Y TTM
74.75%
Sales Y/Y TTM
4.41%
EPS Q/Q
3.72%
Sales Q/Q
5.52%
Insider Own
8.56%
Insider Trans
-2.51%
Inst Own
66.46%
Inst Trans
1.06%
ROA
-17.22%
ROE
-929.32%
ROIC
-20.44%
Gross Margin
32.52%
Oper. Margin
-98.09%
Profit Margin
-81.31%
SMA20
0.23%
SMA50
17.11%
SMA200
40.05%
Trades
Shs Outstand
312.24M
Shs Float
286.13M
52W High
3.43 -34.35%
52W Low
1.07 110.75%
Volatility
13.62% 12.35%
ATR (14)
0.29
RSI (14)
50.35
Beta
2.20
Rel Volume
0.77
Avg Volume
12.38M
Volume
9,564,157
Perf Week
-13.44%
Perf Month
-1.96%
Perf Quarter
96.09%
Perf Half Y
59.93%
Perf YTD
20.59%
Perf Year
26.69%
Perf 3Y
-66.84%
Perf 5Y
-92.27%
Perf 10Y
-67.27%
Prev Close
2.43
Price
2.26
Change %
-7.20%
Analysts 12 incl. previous ratings
Rating Distribution 6 Buy · 5 Hold · 1 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 09, 2026 Resumed U UBS
Neutral $1.35 -40.1% Mar 06, 2026 Downgrade B Barclays
Equal Weight → Underweight $1.50 -33.5% Nov 11, 2024 Downgrade U UBS
Buy → Neutral Jun 03, 2024 Resumed J Jefferies
Buy $4 +77.4% Apr 22, 2024 Downgrade J JP Morgan
Overweight → Neutral Apr 18, 2024 Downgrade G Goldman
Buy → Neutral $7 → $2.50 +10.9% Dec 14, 2023 Initiated S Stephens
Overweight $11 +387.8% Dec 14, 2023 Initiated G Guggenheim
Neutral Dec 13, 2023 Initiated W Wolfe Research
Peer Perform Nov 17, 2023 Upgrade U UBS
Neutral → Buy $13 → $10 +343.5% Oct 31, 2023 Upgrade C Cantor Fitzgerald
Neutral → Overweight $11 +387.8% Sep 28, 2023 Initiated B Bernstein
Outperform $11 +387.8% Jul 05, 2023 Resumed J JP Morgan
Overweight $13 +476.5% Jun 30, 2023 Initiated G Goldman
Buy $17 +653.9% May 10, 2023 Initiated B Barclays
Equal Weight $14 +520.8% Mar 31, 2023 Upgrade T TD Cowen
Market Perform → Outperform $13 → $15 +565.2% Feb 02, 2023 Initiated U UBS
Neutral $13 +476.5% Jan 20, 2023 Downgrade C Cantor Fitzgerald
Overweight → Neutral $12 +432.2% Jan 05, 2023 Initiated B Scotiabank
Sector Outperform $12 +432.2% Jan 21, 2022 Resumed C Cantor Fitzgerald
Overweight $62 → $31 +1,274.7%
Show Previous Ratings
Nov-04-26 07:13PM
05:24PM
04:05PM
Oct-31-26 01:05AM
Oct-27-26 06:58PM
(Earnings Whispers)
+8.89%
+15.51%
04:05PM
Loading…
04:05PM
Oct-19-26 09:05AM
Oct-14-26 04:05PM
Oct-06-26 11:51AM
09:05AM
Oct-01-26 11:44AM
(Schaeffer's Research)
+5.91%
Sep-03-26 04:05PM
Aug-05-26 04:46PM
(Associated Press)
-9.72%
-10.38%
04:08PM
04:05PM
09:05AM
Loading…
09:05AM
Jul-28-26 04:05PM
Jul-15-26 04:05PM
Jun-15-26 02:48PM
May-26-26 09:05AM
May-21-26 04:05PM
May-19-26 09:00AM
May-11-26 09:05AM
May-07-26 04:33PM
(Associated Press)
-14.55%
04:05PM
Apr-21-26 09:05AM
Apr-16-26 04:05PM
Apr-15-26 09:05AM
Mar-18-26 09:05AM
Mar-06-26 02:00PM
09:14AM
Loading…
09:14AM
Mar-05-26 10:57AM
10:56AM
08:30AM
Mar-04-26 09:20AM
07:52AM
Mar-03-26 10:33PM
10:15AM
Feb-27-26 04:15PM
Feb-25-26 11:50AM
Feb-24-26 03:10PM
09:05AM
Feb-20-26 10:48AM
Feb-19-26 11:01PM
12:35AM
Feb-18-26 04:05PM
Feb-13-26 10:24AM
08:21AM
12:03AM
Feb-12-26 08:14PM
05:35PM
04:56PM
04:40PM
(Associated Press Finance)
04:05PM
07:00AM
Feb-10-26 10:04PM
Feb-02-26 09:05AM
Jan-30-26 06:15PM
Jan-27-26 04:05PM
Jan-23-26 06:15PM
Jan-16-26 06:15PM
Jan-15-26 10:35AM
Jan-12-26 09:15AM
09:05AM
09:05AM
Jan-09-26 11:20AM
Jan-08-26 11:01PM
09:05AM
Jan-07-26 06:15PM
12:07PM
Jan-06-26 07:06AM
Jan-05-26 12:23PM
Jan-02-26 11:01AM
08:00AM
Dec-31-25 05:00PM
06:26AM
Dec-30-25 11:49PM
04:05PM
Dec-29-25 12:51PM
Dec-03-25 03:26PM
Nov-28-25 09:05AM
Nov-26-25 09:40AM
Nov-24-25 01:00PM
Nov-18-25 08:48AM
Nov-13-25 04:05PM
12:00PM
Nov-12-25 03:20PM
12:36AM
Nov-11-25 12:26PM
Nov-10-25 10:35PM
Nov-06-25 01:19PM
12:33AM
Nov-05-25 06:30PM
05:55PM
04:54PM
(Associated Press Finance)
04:10PM
04:02PM
09:05AM
Nov-04-25 09:15AM
09:05AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gibson James R II See Remarks Oct 06 '26 Option Exercise 1.18 500,000 590,000 1,745,663 Oct 08 04:07 PM Gibson James R II See Remarks Oct 06 '26 Sale 3.11 661,815 2,056,921 1,083,848 Oct 08 04:07 PM Jim Gibson Officer Oct 06 '26 Proposed Sale 2.87 661,815 1,899,409 Oct 06 04:23 PM Van Oene Mark See Remarks Aug 17 '26 Sale 1.13 26,911 30,409 2,705,853 Aug 18 08:17 PM MARK VAN OENE Officer Aug 17 '26 Proposed Sale 1.13 26,911 30,512 Aug 17 04:08 PM Gibson James R II See Remarks Apr 01 '26 Sale 1.37 88,185 120,813 1,245,663 Apr 03 04:05 PM JAMES GIBSON Officer Apr 01 '26 Proposed Sale 1.37 88,185 120,778 Apr 01 05:17 PM HENRY CHRISTIAN O See Remarks Mar 03 '26 Sale 1.51 12,497 18,920 3,581,813 Mar 04 05:55 PM Van Oene Mark See Remarks Mar 03 '26 Sale 1.51 6,504 9,847 2,243,634 Mar 04 05:54 PM Farmer Michele See Remarks Mar 03 '26 Sale 1.51 2,979 4,510 305,948 Mar 04 05:54 PM MARK D. VAN OENE Officer Mar 03 '26 Proposed Sale 1.51 6,504 9,849 Mar 03 04:24 PM CHRISTIAN HENRY Officer Mar 03 '26 Proposed Sale 1.51 12,497 18,924 Mar 03 04:20 PM Van Oene Mark See Remarks Feb 17 '26 Sale 1.58 129,790 204,549 1,797,745 Feb 19 08:33 PM Van Oene Mark See Remarks Feb 18 '26 Sale 1.63 55,107 89,769 1,742,638 Feb 19 08:33 PM HENRY CHRISTIAN O See Remarks Feb 17 '26 Sale 1.58 331,793 522,906 2,814,374 Feb 19 08:31 PM HENRY CHRISTIAN O See Remarks Feb 18 '26 Sale 1.63 140,874 229,484 2,673,500 Feb 19 08:31 PM Farmer Michele See Remarks Feb 17 '26 Sale 1.58 35,215 55,499 234,044 Feb 19 08:28 PM Farmer Michele See Remarks Feb 18 '26 Sale 1.63 14,952 24,357 219,092 Feb 19 08:28 PM MARK VAN OENE Officer Feb 17 '26 Proposed Sale 1.58 303,739 478,693 Feb 17 06:27 PM CHRISTIAN HENRY Officer Feb 17 '26 Proposed Sale 1.58 606,312 955,548 Feb 17 06:25 PM
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Co-Founder Dr. Stephen Turner Ph.D.